DBV Technologies S.A. (NASDAQ:DBVT) Sees Large Increase in Short Interest

DBV Technologies S.A. (NASDAQ:DBVT) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,330,000 shares, a growth of 297.0% from the October 15th total of 335,000 shares. Based on an average daily trading volume, of 655,300 shares, the short-interest ratio is presently 2.0 days. Currently, 1.4% of the shares of the company are short sold.

DBV Technologies Price Performance

DBVT stock traded down $0.03 during midday trading on Thursday, reaching $0.59. The company had a trading volume of 34,514 shares, compared to its average volume of 230,674. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $2.14. The stock has a 50 day moving average price of $0.73 and a 200-day moving average price of $0.89. The company has a market capitalization of $56.56 million, a price-to-earnings ratio of -0.69 and a beta of 0.66.

DBV Technologies’s stock is set to reverse split on the morning of Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. grew its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies accounts for approximately 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 71.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DBVT. StockNews.com started coverage on shares of DBV Technologies in a report on Thursday. They set a “hold” rating for the company. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a report on Tuesday, September 24th. Finally, HC Wainwright boosted their price target on DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, October 24th.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.